Item 2.02 Results of Operations and Financial Condition




On January 12, 2021, Intersect ENT, Inc. (the "Company") issued a press release
announcing its preliminary expectations of revenue for the fourth quarter ending
December 31, 2020 as well as revenue guidance for the year ending December 31,
2021. A copy of the Company press release is furnished and attached as Exhibit
99.1.

Item 7.01 Regulation FD Disclosure




Members of the Company's management team expect to make a presentation regarding
the Company (the "Presentation") to investors and analysts and to meet with
investors and analysts at the J.P. Morgan Annual Healthcare Conference between
January 11, 2021 and January 14, 2021 to discuss the Presentation. A copy of the
Presentation will be available on the Company's website at www.intersectent.com
in the Investor Relations section.

The information in Items 2.02 and 7.01 and Exhibit 99.1 and of this Current
Report on Form 8-K are being furnished and shall not be deemed "filed" for
purposes of Section 18 of the Securities Exchange Act of 1934 as amended
(Exchange Act), or otherwise subject to the liabilities of that Section of
Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (Securities
Act). The information in Item 2.02 and this Item 7.01 and Exhibit 99.1 shall not
be deemed incorporated by reference in any filing under the Securities Act, or
the Exchange Act, except as expressly set forth by specific reference in such a
filing.


Item 9.01   Financial Statements and Exhibits.


(d) Exhibits
Exhibit
  No.               Description

99.1                  Press release titled "Intersect ENT     Announces

Preliminary Revenue for Fourth


                    Quarter of 2020    " dated January 1    2    , 202    1    .

104                 Cover Page Interactive Data File (formatted as inline XBRL)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses